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Screens for agents that specifically kill epithelial
cancer stem cells (CSCs) have not been possible
due to the rarity of these cells within tumor cell pop-
ulations and their relative instability in culture. We
describe here an approach to screening for agents
with epithelial CSC-specific toxicity. We imple-
mented thismethod in a chemical screen and discov-
ered compounds showing selective toxicity for
breast CSCs. One compound, salinomycin, reduces
the proportion of CSCs by >100-fold relative to pacli-
taxel, a commonly used breast cancer chemothera-
peutic drug. Treatment of mice with salinomycin
inhibits mammary tumor growth in vivo and induces
increased epithelial differentiation of tumor cells. In
addition, global gene expression analyses show
that salinomycin treatment results in the loss of
expression of breast CSC genes previously identified
by analyses of breast tissues isolated directly from
patients. This study demonstrates the ability to iden-
tify agents with specific toxicity for epithelial CSCs.
INTRODUCTION
Studies have identified subpopulations of cells within tumors
that drive tumor growth and recurrence, termed cancer stem
cells (CSCs) (Al-Hajj et al., 2003; Lapidot et al., 1994; Li et al.,
2008; Singh et al., 2003; Smalley and Ashworth, 2003; Stingl
and Caldas, 2007). CSCs are resistant to many current cancer
treatments, including chemo- and radiation therapy (Bao et al.,
2006; Dean et al., 2005; Diehn et al., 2009; Diehn and Clarke,
2006; Eyler and Rich, 2008; Li et al., 2008; Woodward et al.,
2007). This suggests that many cancer therapies, while killingthe bulk of tumor cells, may ultimately fail because they do not
eliminate CSCs, which survive to regenerate new tumors.
CSC representation in cancer cell populations is operationally
measured based on the ability to seed tumors at limiting dilutions
in vivo. CSC-enriched cancer cell populations also exhibit certain
properties in vitro: (1) CSC-enriched subpopulations can be iso-
latedwith cell-surfacemarker profiles (Al-Hajj et al., 2003; Li et al.,
2007a; Ricci-Vitiani et al., 2007; Singh et al., 2003; Zhang et al.,
2008); for example, breast CSCs are enriched in the CD44high/
CD24low subfraction of cells (Al-Hajj et al., 2003). (2) CSC-
enriched populations form spherical colonies in suspension
cultures, termed tumor mammospheres (Dontu et al., 2003) or
tumorspheres. (3) CSC-enriched populations exhibit increased
resistance to chemotherapeutic agents (Bao et al., 2006; Dean
et al., 2005; Diehn and Clarke, 2006; Eyler and Rich, 2008;
Li et al., 2008; Woodward et al., 2007) and ionizing radiation
(Diehn et al., 2009; Woodward et al., 2007).
In principle, the application of automated screening technolo-
gies could facilitate the identification of agents that kill CSCs.
However, since CSCs generally comprise only small minorities
within cancer cell populations, standard high-throughput cell
viability assays applied to bulk populations of cancer cells
cannot identify agents with CSC-specific toxicity. Accordingly,
screening for agents that preferentially kill CSCs depends on
the ability to propagate stable, highly enriched populations of
CSCs in vitro. However, this is not currently possible for the
CSCs of solid tumors. For example, breast CSC enrichment is
rapidly lost during in vitro culture (Fillmore and Kuperwasser,
2008).
The induction of an epithelial-mesenchymal transition (EMT) in
normal or neoplastic mammary epithelial cell populations has
been shown to result in the enrichment of cells with stem-like
properties (Mani et al., 2008). We demonstrate here that normal
and cancer cell populations experimentally induced into an EMT
also exhibit an increased resistance to chemotherapy drug treat-
ment. We exploit this observation to develop and implementCell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc. 645
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a high-throughput screening method to identify agents with
specific toxicity for epithelial CSCs. The results of our screen
and subsequent experiments demonstrate that it is possible to
find agents with strong selective toxicity for breast CSCs.
RESULTS
CSC Numbers Are Increased in Breast Cancer Cells
Induced into an EMT
We sought to increase the proportion of CSCs in breast cancer
cell populations by inducing them to pass through an EMT. To
this end, wemodified experimentally transformedHMLERbreast
cancer cells (Elenbaas et al., 2001) by short hairpin RNA
(shRNA)-mediated inhibition of the human CDH1 gene, which
encodes E-cadherin. Confirming previous results, an shEcad
vector triggered an EMT and resulted in acquisition of a mesen-
chymal phenotype (Figure 1A) (Onder et al., 2008). Moreover,
expression of a murine E-cadherin gene resistant to the intro-
duced human shEcad construct caused reversion of EMT-asso-
ciated phenotypes, indicating that EMT induction was not due to
off-target shRNA effects (Figure 1A).
We next examined whether HMLER cancer cell populations
induced through an EMT displayed an increase in the proportion
of cells carrying the CD44high/CD24low marker profile associated
with human mammary CSCs. We observed that the percentage
of CD44high/CD24low cells was 10-fold higher in HMLERshEcad
cells than in control cells (HMLERshCntrl) (90% versus 8%;
Figure 1B). A similar increase was observed in HMLER cells
induced to undergo EMT by expression of Twist, a transcription
factor whose ability to program an EMT is well documented
(Mani et al., 2008; Yang et al., 2004).
We next tested the ability of HMLERshEcad cells to form tumor-
spheres when grown in suspension cultures, an in vitro measure
of CSC activity. HMLERshEcad cells showed an 100-fold
increase in tumorsphere-forming ability relative to HMLERshCntrl
cells (15 spheres versus 0.15 spheres per 100 cells;
Figure 1C). We also directly assayed the ability of HMLERshEcad
cells to seed tumors in mice. Tumors were generated with 1000
HMLERshEcad cells, which was 100-fold less than was required
for tumor seeding by HMLERshCntrl cells (Figure 1D). While dis-
playing increased CSC activity, the HMLERshEcad cells prolifer-
ated more slowly than the HMLERshCntrl cells (Figure 1E). Thus,
using all established measures of CSC activity, HMLER breast
cancer cell populations that had undergone an EMT containeda significantly greater proportion of CSCs relative to control
cell populations.
Normal and Neoplastic Cells Induced to Pass through
an EMT Exhibit Increased Drug Resistance
Drug treatment of cancer cell populations leads to a concomitant
enrichment for CSCs (Levina et al., 2008) and for cells that have
undergone an EMT (Eyler and Rich, 2008; Thomson et al., 2005;
Yang et al., 2006; Yauch et al., 2005). We therefore examined
whether breast cancer cell populations that have been experi-
mentally induced into EMT also share this aspect of CSC
biology, namely an increased resistance to chemotherapeutic
drugs. We found that HMLERshEcad cells were more resistant
than HMLERshCntrl cells to two commonly used chemothera-
peutic drugs, paclitaxel (20-fold increase in IC50) and doxoru-
bicin (5-fold increase) (Figure 1F). Taken together with the
above observations, these findings indicated that breast cancer
cell populations induced into EMT were operationally indistin-
guishable from populations enriched for CSCs using cell-surface
markers.
Cancer cells often carry uncharacterized genetic alterations,
some of which could contribute in important ways to the
increased drug resistance observed after EMT induction. We
therefore examined whether untransformed epithelial cells also
exhibited increased drug resistance after EMT induction. We
studied HMLE cells, which are immortalized mammary epithelial
cells that differ from HMLER cells in that they lack an introduced
HrasV12 oncogene and are nontumorigenic. Similar to the trans-
formed HMLERshEcad cells, when E-cadherin was downregu-
lated in these cells through shRNA-mediated inhibition, the
resulting HMLEshEcad cells underwent an EMT and were found
to contain an 80-fold increase in the proportion of CD44high/
CD24low cells relative to HMLEshCntrl controls (Figure 1B). In addi-
tion, like HMLERshEcad cells, the nontumorigenic HMLEshEcad
cells exhibited increased resistance (10- to 20-fold) to paclitaxel
and doxorubicin relative to control cells not induced into EMT
(Figure 1G). In fact, HMLEshEcad cells were also more resistant
than HMLEshCntrl cells to other established chemotherapeutic
drugs, including actinomycin D, camptothecin, and staurospor-
ine, a broad-spectrum kinase inhibitor (Figure 1G). These results
indicated that the increased drug resistance observed after EMT
induction is not a consequence of neoplastic transformation.
We next examined whether the increased drug resistance
associated with cells induced to pass through an EMT wouldFigure 1. Mesenchymally Transdifferentiated Breast Epithelial Cells Have Increased Numbers of CSCs and Are Drug Resistant
(A) Western blotting for E-cadherin, b-catenin, and b-actin in HMLER cells expressing shRNA against either GFP (shGFP) or the human CDH1 gene (shEcad).
Stable introduction of a murine ECAD gene (p.mEcad) but not GFP (p.GFP) results in re-expression of E-cadherin protein and reversal of EMT-associated
morphology.
(B) FACS with CD24 and CD44 markers. The percentage of the CD44+/CD24 subpopulation is indicated.
(C and D)Mammosphere formation assays (C) and tumor-seeding (D) with HMLERshCntrl and HMLERshEcad breast cancer cells. Bars in (C) denote the standard
error (n = 12).
(E) Proliferation curves of HMLER-shCntrl and HMLER-shEcad cells grown in culture. Viable cells were counted by Trypan Blue dye exclusion. Bars denote the
standard error (n = 5).
(F) Dose-response curves of HMLERshEcad and HMLERshCntrl breast cancer cells treated with doxorubicin or paclitaxel. Bars denote the standard error (n = 5).
(G) Viability of immortalized, non-tumorigenic breast epithelial cells (HMLE shCntrl) and cells induced through EMT (HMLEshEcad) treated with various chemo-
therapy compounds. Bars denote the standard error (n = 5).
(H) Proportion by FACS of GFP-labeled HMLEshEcad cells after paclitaxel treatment when mixed with control cells (HMLE) cells. Bars denote the standard error
(n = 3).Cell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc. 647
select for the preferential outgrowth of such cells after drug treat-
ment in vitro. Accordingly, we treated cocultures of green fluo-
rescent protein (GFP)-labeled HMLEshEcad cells and unlabeled,
unfractionated HMLEshCntrl cells (1:20 ratio) with paclitaxel in
culture. Treatment for 4 days with paclitaxel (10 nM) resulted in
a 4-fold increase in the proportion of HMLEshEcad cells compared
to DMSO-treated cocultures (Figure 1H), indicating that pacli-
taxel treatment leads to the selective outgrowth of cells that
have undergone an EMT.
Identification via High-Throughput Screening
of Compounds with EMT-Specific Toxicity
The results above indicated that (1) breast cancer cells that have
undergone an EMT exhibited an100-fold increase in CSCs and
that (2) the responses of immortalized nontumorigenic epithelial
cells (HMLE) to drug treatment closely paralleled the drug
treatment responses of their neoplastically transformed HMLER
derivatives. Having also observed that HMLEshEcad cells exhibit
increased resistance to commonly used chemotherapeutic
drugs, we speculated that agents that selectively target these
nontransformed cells might also be found subsequently to
exhibit selective toxicity toward CSCs.
Based on this reasoning, we designed a proof-of-concept
screen to identify agents that selectively target mesenchymally
transdifferentiated breast epithelial cells. We therefore screened
test compounds for their effects on HMLEshEcad and control
HMLEshCntrl cells. Cells from each cell line were seeded in
384-well plates, allowed to proliferate for 1 day, treated with
test compounds, and assayed for cell viability 3 days later with
a luminescence assay; compounds were screened in duplicate
for each cell line (Figure 2A; Experimental Procedures). We
screened a collection of 16,000 compounds, which included
several diverse commercial libraries, as well as collections of
natural extracts; many of the compounds in these collections
had known bioactivity (Experimental Procedures).
About 10% of the tested compounds reduced the viability of
HMLEshEcad cells, but the vast majority (98%) of this set of
compounds also reduced the viability of the control HMLEshCntrl
cells. Only 32 compounds (0.2% of total library) exhibited
selective toxicity toward the HMLEshEcad cells (Figure 2B).
Among the 100 commonly used chemotherapeutic drugs con-
tained in this large compound library, the proportion of hits was
not significantly higher, with only three showing any evidence of
selective toxicity toward the HMLEshEcad cells.
We selected eight of these 32 compounds for further study,
based on their availability, and evaluated their effects across
a range of doses. Upon retesting, four of these eight compounds
showed consistent evidence of selective toxicity toward
HMLEshEcad cells (Figure 3A). The chemical identities of these
four compounds were confirmed with high-resolution mass
spectrometry (data not shown). Three of these compounds
(etoposide, salinomycin, and abamectin) showed moderate-to-
strong selectivity (IC50 10-fold lower for HMLEshEcad cells than
HMLEshCntrl cells); the fourth, nigericin, showed more modest
selectivity (7-fold). The four compounds that selectively
inhibited the immortalized HMLEshEcad human mammary epithe-
lial cells also preferentially killed cells that had undergone an
EMT because of forced expression of the Twist transcription648 Cell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc.factor (HMLETwist; Figure 3B; Figure S1 available online).
Thus, the dose-response curves of these four compounds for
HMLETwist cells were essentially identical to those observed for
HMLEshEcad cells (Figure 3B). These results suggest that the
selectivity of these compounds is independent of the particular
mechanism used to induce mesenchymal transdifferentiation
and the associated acquisition of stem cell traits.
While these four compoundswere identified as selective inhib-
itors of immortalized human breast epithelial cells (HMLEshEcad)
that had undergone an EMT, it was not clear whether they would
also exhibit a selective effect on the corresponding tumorigenic
cells (HMLERshEcad). In fact, across a range of concentrations,
salinomycin was selectively toxic for the HMLERshEcad cells
(8-fold selectivity), while the remaining three compounds (aba-
mectin, etoposide, and nigericin) displayed only a modest selec-
tive toxicity (2-fold) toward the HMLERshEcad cells, in all cases
relative to the HMLERshCntrl cells (Figure 3C).
Salinomycin Selectively Kills Breast CSCs
In response to these various observations,we focusedour further
investigations on theproperties of salinomycin.Weobserved that
the sensitivity of breast cancer cell lines to salinomycin correlated
with the relative abundance of their CD44high/CD24low CSC-
enriched subpopulations (Figure S2). Accordingly, we sought to
assess the specific effects of salinomycin on CSCs that existed
naturally as a subpopulation within HMLER breast cancer cells
rather than in populations experimentally induced into an EMT.
For these and subsequent compound-treatment experiments,
we treated cells for a specified time, allowed cells to recover for
4 days, and then conducted subsequent experimental assays
in the absence of additional treatment, since this protocol would
ensure that any further toxicity in the continued presence of
a chemical compound would not confound the results of assays
used to measure CSC representation.
We first assayed the effects of treatment on the proportion of
breast cancer cells with the CD44high/CD24low antigenic pheno-
type (Al-Hajj et al., 2003). Salinomycin treatment decreased the
proportion of CD44high/CD24low breast cancer cells by 20-fold
relative to vehicle-treated controls; in contrast, paclitaxel treat-
ment increased the proportion by 18-fold. The relative size of the
CD44high/CD24low fractionwas therefore360-fold lowerafter treat-
ment with salinomycin than with paclitaxel (HMLER_1, Figure 4A).
Ina secondexperimentwithan independent populationofHMLER
breast cancer cells that naturally contains a high proportion of
CSCs, we observed an 75-fold reduction in the proportion of
CSCs after salinomycin treatment compared to control treatment
(HMLER_2, Figure 4A).Weobservedcomparable resultswith cells
of the SUM159 human breast carcinoma line (Figure S3).
As a functional measure of CSC frequency, we also examined
the ability of HMLER breast cancer cells to form tumorspheres
after treatment with salinomycin, paclitaxel, or dimethyl sulfoxide
(DMSO) control. Salinomycin treatment induced an 10-fold
decrease in the number of tumorspheres relative to controls
(Figure 4B). In contrast, paclitaxel treatment did not affect the
number of tumorspheres formed, resulting instead in a significant
increase in tumorsphere size.
We speculated that the inability of paclitaxel treatment to
increase relative tumorsphere numbers was due to the already
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Figure 2. Chemical Screening for Compounds that Selectively Kill Mesenchymally Transdifferentiated Immortalized Epithelial Cells
(A) Schematic of the screen design and protocol.
(B) (i) Histogram of replicate-averaged background-corrected viability signal intensities (see the Experimental Procedures for details) for the viability of each
tested compound for control breast epithelial cells (HMLEshCntrl). Low/high signal intensities indicate compounds that reduce/increase cell viability. (ii) XY-Scatter
plot of normalized Z scores for the viability of each tested compound for mesenchymally transdifferentiated breast epithelial cells (HMLEshEcad; red dots indicate
DMSO treatment; blue dots indicate test compounds). ‘‘Z-scoreA’’ and ‘‘Z-scoreB’’ represent the normalized Z scores for the two independent replicates of the
screen. (iii) The data are as in (i) with the red shaded region in the histogram representing compounds that exhibited mild-to-strong toxicity (>1 SD lower than
themean normalized signal intensity) for the control HMLEshCntrl epithelial cells. Compoundswithin the red region in (iii) were filtered out of the plot in (ii), producing
the scatter plot in (iv). Application of this selectivity filter resulted in the identification of compounds that selectively killed mesenchymally transdifferentiated
HMLEshEcad but not control HMLEshCntrl epithelial cells (yellow dots).high proportion of CSCs present in the HMLERbreast cancer cell
line used in this assay. To address this issue directly, we
controlled the proportion of CSCs in the test population by
reconstructing a mixed population of CSCs and non-CSCs; we
did this by admixing cells that had been forced to undergo an
EMT with control cells that had not undergone this transition.
This resulted in a representation of CSCs that allowed both posi-tive and negative effects on CSC numbers to be assayed within
a single cancer cell population (termed HMLER_Mx).
Salinomycin treatment decreased the proportion of CD44high/
CD24low HMLER_Mx cells by 4-fold relative to vehicle-treated
controls; in contrast, paclitaxel treatment increased the propor-
tion of CD44high/CD24low HMLER_Mx cells by 4-fold. The relative
proportion of CD44high/CD24low HMLER_Mx cells was thereforeCell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc. 649
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Figure 3. Identification and Validation of Compounds that Exhibit Selective Toxicity for Mesenchymally Transdifferentiated Epithelial Cells
(A) Chemical structure of salinomycin, etoposide, abamectin, and nigericin and dose-response curves of control HMLE-shCntrl cells and HMLE-shEcad cells
treated with indicated compounds.
(B) Dose-response curves of the viability of HMLE-shCntrl and HMLE-Twist cells.
(C) Dose-response curves of control HMLER and HMLER-shEcad tumorigenic mammary epithelial cells treated with salinomycin, etoposide, abamectin, or
nigericin.
Bars denote the standard error with n = 6 for each treatment combination.16-fold lower after treatment with salinomycin than with pacli-
taxel (Figure 4C). Similarly, treatment of immortalized nontumori-
genic HMLE_Mx cells with salinomycin reduced the fraction of
CD44high/CD24low HMLE_Mx cells 4-fold, whereas paclitaxel
treatment increased the fraction of CD44high/CD24low HMLE_Mx
cells 4-fold (Figure 4C).
We also examined the effects of drug treatment on the ability
of either breast cancer (HMLER_Mx) or immortalized mammary
epithelial (HMLE_Mx) cells to form colonies in suspension
culture. Sphere-forming ability in suspension cultures is corre-650 Cell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc.lated with CSC numbers in cancer cell lines and with progenitor
activity in untransformed mammary epithelial cells (Dontu et al.,
2003). Salinomycin treatment resulted in a 13-fold decrease in
the number of HMLER_Mx tumorspheres relative to controls
(Figure 4D). In contrast, paclitaxel treatment induced a 2-fold
increase in the number of HMLER_Mx tumorspheres relative to
vehicle treatment; as before, paclitaxel also caused a significant
increase in HMLER_Mx tumorphere size (Figure 4D).
Salinomycin treatment also reducedmammosphere formation
by nontumorigenic HMLE_Mx populations (>10-fold; Figure 4D).
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Figure 4. Effect of Salinomycin and Paclitaxel Treatment on Breast CSC Numbers
(A) HMLER cells were treated with DMSO, paclitaxel, or salinomycin at the specified doses for 4 days, and then allowed to recover in the absence of treatment for
4 days. The percent of CD44high/CD24low cells after compound treatment in independent experiments with two different HMLER cell populations (HMLER_1,
HMLER_2) is shown. Bars denote the standard error (n = 3). The CD44/CD24 FACS profiles are shown for a subset of HMLER_2 compound treatments with
the green ellipse denoting the CSC-enriched fraction and the blue ellipse the CSC-depleted fraction.
(B) Quantification of tumorsphere-formation with HMLER cells treated as in (A). Bars denote the standard error for n = 5.
(C) Heterogeneous populations (control/EMT mixtures) of HMLE and HMLER cells (HMLE_Mx, HMLER_Mx, respectively) were compound treated for 4 days,
cultured in the absence of compound for 4 days, and the percent of CD44high/CD24low cells was quantified by FACS. Bars denote the standard error (n = 3).
(D) Quantification of mammosphere-formation in HMLE_Mx and HMLER_Mx populations compound-treated as in (A). Bars denote the standard error (n = 10).
Phase-contrast images of mammospheres are shown.
(E) In vitro growth curves of HMLER cells compound-treated as in (A) are shown.
(F) Compound-pretreated MCF7Ras (4000 cells/well) and 4T1 cells (1000 cells/well) were seeded in the absence of compound and tumorsphere formation
assessed at 10 days. Bars denote the standard error (n = 3).
(G) The fraction of viable cells after compound treatment was assessedwith trypan-blue exclusion for both the parental 4T1 line and a paclitaxel-resistant 4T1 line
(4T1-TaxR). Bars denote the standard error for proportions (n = 4).In contrast, paclitaxel treatment did not affect the number of
HMLE_Mx mammospheres relative to vehicle-treated controls
(Figure 4D). Proliferation in monolayer cultures was not inhibited
by salinomycin treatment relative to either vehicle or paclitaxel
treatment (Figure 4E), indicating that salinomycin’s inhibition of
CSC viability was not a consequence of a general inhibition of
cell proliferation.We next examined the effects of salinomycin, paclitaxel, and
DMSO treatment on two additional breast cancer cell lines—
a mouse mammary tumor line (4T1) and a human breast cancer
line (MCF7Ras). Salinomycin treatment led to an 3-fold reduc-
tion in CSC numbers as gauged by tumorsphere-forming poten-
tial for MCF7Ras cells and an 2-fold reduction for 4T1 cells
relative to control DMSO treatment (Figure 4F). In contrast,Cell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc. 651
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Figure 5. Effects of Salinomycin and Paclitaxel Treatment on Tumor Seeding, Growth and Metastasis In Vivo
(A) Tumor-seeding ability of HMLER and 4T1 breast cancer cells treated with salinomycin, paclitaxel, or DMSO.
(B) SUM159 tumor-growth curves of compound-treated mice. Error bars denote the standard error (n = 10).
(C) Quantification of tumorsphere-forming potential (diameter between 20 and 50 mm was evaluated) of cancer cells isolated from dissociated SUM159 tumors
from compound-treated mice. Error bars denote the standard error (n = 5). Images of tumorsphere cultures are shown.
(D) Histological analysis of tumors from salinomycin- or vehicle-treated mice. Shown are H&E, caspase-3, human-specific vimentin, and E-cadherin staining.652 Cell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc.
paclitaxel treatment caused an3-fold increase in tumorsphere-
forming potential of the MCF7Ras cells and an 2-fold increase
for 4T1 cells relative to DMSO vehicle treatment (Figure 4F).
Notably, for both 4T1 andMCF7Ras cells, salinomycin treatment
selected for cells with morphologic features associated with
increased epithelial differentiation relative to DMSO-treated
controls (Figure S4; data not shown). In contrast, paclitaxel treat-
ment selected for cells exhibiting a mesenchymal and migratory
phenotype (Figure S4).
We observed that 4T1 cells treated with paclitaxel for 4 days
and then allowed to recover in the absence of drug for 4 days
(4T1-TaxR cells) were resistant to further paclitaxel treatment
in comparison to parental 4T1 cells that had not been previously
treated with paclitaxel (Figure 4G). In contrast, the 4T1-TaxR
cells, while resistant to paclitaxel, displayed a 2-fold increase
in sensitivity to treatment with salinomycin in comparison to
parental 4T1 cells (Figure 4G). These observations demonstrate
that treatment with paclitaxel selects for mesenchymal cancer
cells that display increased resistance to paclitaxel while remain-
ing sensitive to salinomycin treatment.
Effects of Salinomycin andPaclitaxel on Tumor Seeding,
Growth, and Metastasis
We also assessed the functional presence of CSCs by assaying
for in vivo tumor-seeding ability after chemical compound treat-
ment in vitro. For these experiments, HMLER and 4T1 cancer
cells were treated with compounds in vitro for 7 days, allowed
to recover and expand in culture for at least 14 days in the
absence of treatment, and then injected in serial limiting dilutions
into mice. We observed that salinomycin pretreatment resulted
in a >100-fold decrease in tumor-seeding ability relative to pacli-
taxel pre-treatment for both the HMLER and 4T1 cancer lines
(Figure 5A). These findings indicated that CSCs within breast
cancer cell populations are resistant to paclitaxel but sensitive
to treatment with salinomycin.
We next treated mice that had been injected orthotopically
with SUM159 human breast cancer cells with paclitaxel
(5 mg/kg), salinomycin (5 mg/kg), or vehicle, administered daily.
While palpable tumors developed in vehicle-treated mice within
1.5 weeks, paclitaxel and salinomycin treatment both delayed
palpable tumor formation by 2 weeks. Subsequent tumor size
in salinomycin-treated animals was reduced relative to tumors in
vehicle-treated animals (Figure 5B). While tumor size reduction
relative to vehicle-treated controls was comparable for salino-
mycin- and paclitaxel-treated mice, the latter cohort exhibited
a reduced tumor size at later time points (Figure 5B). Four weeks
after cancer cell injection, tumors were analyzed for the pres-
ence of surviving CSCs with in vitro tumorsphere formation
assays. Tumors from the paclitaxel-treated cohort had a 2-fold
increase in tumorsphere-forming cells relative to either salinomy-
cin- or vehicle-treated cohorts (Figure 5C).
Tumors from salinomycin-treated mice had increased
necrosis and apoptosis compared to comparably sized tumorsfrom vehicle-treated mice (Figure 5D). Viable cancer cells in
tumors from salinomycin-treated mice were mostly restricted
to the periphery of the tumor mass (Figure 5D). E-cadherin
protein, which is not normally expressed in the SUM159 line,
was focally expressed specifically in tumors from salinomycin-
treated mice and not in tumors from control vehicle-treated
mice (Figure 5D). Cells that expressed E-cadherin protein dis-
played a more differentiated epithelial morphology, suggesting
that salinomycin treatment had either induced SUM159 cancer
cells to differentiate in vivo or selected for the expansion
in vivo of SUM159 cancer cell subpopulations displaying
increased epithelial differentiation.
CSCs have been proposed to be responsible for colonization
at secondary organ sites upon metastatic dissemination (Li
et al., 2007b; Croker and Allan, 2008). We therefore examined
whether the reduction in CSC numbers after salinomycin treat-
ment was also accompanied by a reduction in metastatic
nodule-forming ability. To specifically assay for the final step of
metastasis, we seeded 4T1 cancer cells into the lungs of synge-
neic animals via tail-vein injection. 4T1 cells pretreated in vitro
with salinomycin displayed a 4-fold reduction in metastasis
burden after 3 weeks growth in vivo compared to vehicle-pre-
treated cells (Figure 5E). In contrast, 4T1 populations pretreated
with paclitaxel exhibited a 2-fold increase in metastasis forma-
tion relative to the vehicle-pretreated control cohort (Figure 5E).
Wenext stained lungs from4T1metastasis-bearing animals for
markers of epithelial differentiation (E-cadherin) and EMT
(vimentin). Lung nodules formed by paclitaxel-treated 4T1 cells
displayed increased vimentin staining and decreased E-cadherin
staining relative to nodules formed by DMSO-treated 4T1 cells
(Figure 5F). In contrast, salinomycin-treated 4T1 cells formed
lung nodules with increased E-cadherin and reduced vimentin
expression relative to nodules formed by DMSO-treated 4T1
cells (Figure 5F). Furthermore, 4T1 cells explanted and cultured
from lung nodules displayed differences in morphology; pacli-
taxel-treated 4T1 cells showed a mesenchymal morphology,
whereas salinomycin-treated 4T1 cells showed a morphology
associated with epithelial differentiation (Figure 5F). Together
with our previous observations (Figure S4), these results indi-
cated that paclitaxel and salinomycin treatment exert opposing
effects on the differentiation state of breast cancer cells, with
the former inducing an increase inmesenchymal transdifferentia-
tion and the latter inducing an increase in epithelial differentiation
relative to treatment with DMSO vehicle. Moreover, these alter-
ations in differentiation state were metastable, remaining
throughout the 3 week period of growth in vivo.
Reduced Expression of CSC-Associated Genes after
Salinomycin Treatment
To determine whether our observations with cultured human
breast cancer cells were representative of breast CSCs naturally
present in mammary carcinomas, we performed comparative
global gene expression analyses on three populations of HMLER(E) Tail-vein injection of 4T1 cancer cells, pre-treated with paclitaxel, salinomycin, or DMSO. Lung images shown were captured at 1.53 magnification. Lung
tumor surface area shown below the images are (mean ± SE)/10ˆ 6 for n = 5.
(F) H&E, vimentin, and E-cadherin staining of lung nodules from compound-treated 4T1 breast cancer cells. Also shown are images of cultured 4T1 cells
explanted from lung nodules.Cell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc. 653
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Figure 6. Salinomycin and Paclitaxel Treatment Affect Expression of CSC Genes Associated with Poor Patient Prognosis
HMLER cells were treated in triplicate with either salinomycin or paclitaxel and then subjected to microarray gene expression analysis.
(A) Genes showing differential expression (jt statisticj > 5) between salinomycin (Sal) and paclitaxel (Tax) treatment conditions were plotted on the Heatmap using
the Euclidean distance measure.
(B–D) Salinomycin treatment reduces the expression of clinically relevant breast CSC and progenitor genes. Gene set enrichment analysis was used to determine
whether the previously reported CD44+CD24 IGS (Liu et al., 2007) (B), CD44+CD24 (Shipitsin et al., 2007) (C), or Mammosphere (Dontu et al., 2003) (D) gene
sets were repressed in response to salinomycin in comparison with paclitaxel treatment. Graphed are the Kolmogorov-Smirnov enrichment scores versus Gene
ranks based on differential expression. p values reflecting statistical significance for each analysis are shown. The rank of each gene in the gene set relative to the
differential expression between salinomycin and paclitaxel treatment are shown as horizontal lines in the vertical bars next to each graph.breast cancer cells treated in parallel with either salinomycin or
paclitaxel (Figure 6A). We then applied gene set enrichment
analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005)
to test whether genes that had been previously associated
with either breast CSCs or normalmammary epithelial progenitor
cells were related to those downregulated upon treatment of
HMLER breast cancer cells with salinomycin relative to pacli-
taxel treatment.
The first gene set tested, termed the invasiveness gene signa-
ture, was generated by comparison of the expression profiles of
CD44highCD24low tumorigenic breast cancer cells with expres-
sion profiles from normal mammary epithelium (Liu et al.,
2007). A previous report has suggested that this signature is
correlated inversely with both metastasis-free survival and over-
all survival for four different types of tumors (Liu et al., 2007). The
97 genes that were upregulated in this signature constituted the654 Cell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc.CD44+CD24 IGS gene set. GSEA revealed a significant reduc-
tion in the expression of genes in this set upon treatment with sal-
inomycin compared with paclitaxel treatment (p < 6 3 103,
CD44+CD24 IGS gene set, Figure 6B). The second gene set,
termed the CD44vs.CD24 gene set, was generated by
comparing SAGE expression data from either CD44high or
CD24high cells purified directly from human breast cancers (Shi-
pitsin et al., 2007). This set consists of 41 genes upregulated in
CD44high cells that also exhibited prognostic value for breast
cancer patient clinical outcomes. GSEA indicated a significant
reduction in the expression of the genes in this set upon treat-
ment of cultured breast cancer cells with salinomycin compared
with paclitaxel treatment (p < 2.9 3 102, CD44vs.CD24,
Figure 6C).
The third gene set—the Mammosphere gene set (31 genes)—
was obtained by comparison of the expression profiles of normal
mammary epithelial cells obtained from human patients cultured
under conditions that favor mammary epithelial stem cell expan-
sion with the expression profiles of cells cultured under condi-
tions favoring their differentiation (Dontu et al., 2003). GSEA
indicated that expression of the mammosphere-specific genes
was preferentially lost upon treatment with salinomycin com-
pared with paclitaxel treatment (p < 5 3 104, Mammosphere,
Figure 6D).
The depletion of these gene sets in salinomycin-treated cells
suggests an overlap between the mammary epithelial cell states
associated with normal and neoplastic CD44highCD24low cells,
seeding of mammospheres, and passage through an EMT. To
identify genes concordantly regulated in all of these three cell
states, we compared genes exhibiting strong differential expres-
sion in (1) paclitaxel- versus salinomycin-treated HMLER cells,
(2) primary humanmammary epithelial cells grown in suspension
sphere versus adherent culture conditions (Dontu et al., 2003),
and (3) CD44+ versus CD24+ normal and neoplastic primary
human mammary epithelial cells (Shipitsin et al., 2007).
We found 25 genes that showedmore than 3-fold upregulation
across all three of the comparisons and 14 genes that showed
a greater than 3-fold downregulation across all three compari-
sons (Table 1). Notably, almost all of the coordinately regulated
genes encoded proteins that were either membrane-associated
or secreted factors, the latter of which included multiple compo-
nents of the extracellular matrix. This indicates that these genes
and their products are associated with specific phenotypes of
the normal and neoplastic stem cell states.
DISCUSSION
Given the variety of therapies to which they are resistant, it is
possible that CSCs would exhibit a generalized resistance to
apoptosis, suggesting that it might not be possible in practice
to find therapies that specifically target CSCs. Here, we demon-
strate that this is not the case and that it is in fact possible to
use unbiased screening strategies to systematically identify
chemical compounds that specifically target breast CSCs. The
approach described here can be extended to other epithelial
cancer types and implemented using any reagent collection
compatible with high-throughput screening, including RNA inter-
ference (RNAi), antibody, or complementary DNA (cDNA)-over-
expression libraries.
As shown here, salinomycin preferentially targets the viability
of CSCs within breast cancer cell populations. Moreover, salino-
mycin but not paclitaxel treatment results in the loss of expres-
sion of CSC-associated genes correlated with poor-prognosis
tumors. This finding indicates that breast CSCs in culture have
a molecular phenotype that reflects the in vivo biology of
CSCs, since the poor-prognosis CSC-associated gene sets
examined here were compiled from two independent studies
using tissues isolated directly from patients. Moreover, the
subset of genes coordinately expressed in CSCs and downregu-
lated in salinomycin-treated cells (Table 1) may serve as useful
biomarkers for identifying breast tumors that would be respon-
sive to anti-CSC therapies.
The screen reported here was carried out with genetically well-
defined immortalized mammary epithelial cells that were nottumorigenic. This experimental design was adopted to minimize
the likelihood of finding compounds that depend on undefined
genetic alterations in order to selectively kill cells that have under-
gone an EMT. The observation that compounds identified by
screening with nontumorigenic cells also target CSCs provides
further evidence linking the CSC state with EMT (Mani et al.,
2008). Moreover, this observation suggests a new avenue for
the development of antitumor therapies. To date, rational cancer
therapies have been designed to target specific genetic alter-
ations present within tumors. The findings here indicate that
a second approach may also prove useful—namely, searching
for agents that target specific states of cancer cell differentiation.
Accordingly, future therapies could offer greater possibilities for
individualized treatment by considering both the genetic alter-
ations and differentiation states present within the cancer cells
of a tumor at the time of diagnosis.
The mechanism(s) by which salinomycin, a potassium iono-
phore, induces breast CSC-specific toxicity remains unclear.
Nigericin, another potassium ionophore bearing structural
similarity to salinomycin, also exhibited selective toxicity for
HMLEshEcad cells both in our primary screen and in follow-up vali-
dation. Further studies will be required to characterize the
connection between potassium membrane potential and CSC
biology.
An important future direction would be extending the findings
reported here to primary tumor cells directly explanted from
patients. However, such studies will have to surmount two signif-
icant technical challenges: (1) only 20% of patient-derived
breast cancers can currently be successfully engrafted directly
into immunocompromised murine hosts and (2) the genetic
and histopathologic variability among patient tumors at the
time of surgical resection would confound any comparisons of
the effects of drug treatment across different xenograft-bearing
animals in vivo. Thus, such an experimental designwould require
a large number of primary tumor samples derived from patients
diagnosed with the same subtype of breast cancer and would
ideally stratify for genetic background.
The importance of targeting CSCs derives from the multiple
observations showing that CSCs, in addition to having increased
tumor-seeding potential, are resistant to a variety of chemo-
therapy drugs and radiation treatment. As is shown here and
elsewhere (Fillmore and Kuperwasser, 2008), treatment with
paclitaxel actually imposes a strong selection for CSC survival
and expansion. This suggests that in caseswhere chemotherapy
or radiation treatment fail to completely eradicate the disease,
the residual cancer cells will be highly enriched for cells that
persist in a CSC/mesenchymal state. This notion is supported
by recent clinical observations showing that after conventional
chemotherapy, breast tumors have an increased proportion of
cells with a CD44hi/CD24lo marker profile and increased tumor-
sphere-forming ability (Li et al., 2008). Collectively, these consid-
erations indicate that to be effective in the long-term, cancer
therapies should include agents that target CSCs to prevent
the regrowth of neoplastic cell populations.
It is conceivable that non-CSCs within tumors can give rise to
CSCs at a low but significant rate. It is also possible that the
elimination of the CSCs within a tumor may not result in its
complete regression, since non-CSCs, while less aggressive,Cell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc. 655
Table 1. Genes Differentially Expressed in Both Compound-Treated—Paclitaxel versus Salinomycin—Cancer Cells and in Normal and
Neoplastic Breast Epithelial Populations Enriched for Stem-like Cells
Affymetrix ProbeID
Paclitaxel vs.
Salinomycin
Sphere vs.
Adherent
CD44+ vs.
CD24+ Gene Symbol Gene Description
Upregulated in Breast CSCs
202403_s_at 21.53 4.51 22.1 COL1A2 collagen, type I, alpha 2
209392_at 16.99 4.88 18.65 ENPP2 ectonucleotide pyrophosphatase
202465_at 12.8 22.67 5.22 PCOLCE procollagen endopeptidase enhancer
207173_x_at 11.21 14.93 20.15 CDH11 cadherin 11, type 2, OB-cadherin
209156_s_at 9.2 21.87 22.68 COL6A2 collagen, type VI, alpha 2
202283_at 9 12.06 24.62 SERPINF1 serpin peptidase inhibitor, clade F
212667_at 8.59 4.24 24.27 SPARC secreted protein, acidic, cysteine-rich
202766_s_at 8.19 5.13 21.64 FBN1 fibrillin 1
218162_at 7.39 >10 15.33 OLFML3 olfactomedin-like 3
202310_s_at 6.4 17.31 19.37 COL1A1 collagen, type I, alpha 1
212158_at 6.27 4.99 5.97 SDC2 syndecan 2
213869_x_at 5.87 >10 52.34 THY1 Thy-1 cell surface antigen
212154_at 5.82 5.36 5.97 SDC2 syndecan 2
201508_at 4.76 8.5 8.78 IGFBP4 insulin-like growth factor BP4
212091_s_at 4.69 >10 15.86 COL6A1 collagen, type VI, alpha 1
203186_s_at 4.52 6.73 6.31 S100A4 S100 calcium binding protein A4
211981_at 4.28 >10 31.52 COL4A1 collagen, type IV, alpha 1
210809_s_at 4.23 5.55 36.56 POSTN periostin
212298_at 4.1 5.11 8.95 NRP1 neuropilin 1
211966_at 4.01 >10 31.52 COL4A2 collagen, type IV, alpha 2
211709_s_at 3.82 3.53 18.65 CLEC11A C-type lectin domain family 11
201525_at 3.71 >10 11.96 APOD apolipoprotein D
203729_at 3.62 6.12 5.21 EMP3 epithelial membrane protein 3
210201_x_at 3.38 3.07 17.14 BIN1 bridging integrator 1
209081_s_at 3.19 31.08 10.11 COL18A1 collagen, type XVIII, alpha 1
Downregulated in Breast CSCs
209529_at 3.48 <-10 6.62 PPAP2C phosphatidic acid phosphatase 2C
219976_at 3.64 <-10 4.96 HOOK1 hook homolog 1 (Drosophila)
202023_at 5.46 <-10 5.54 EFNA1 ephrin-A1
205286_at 5.76 3.62 8.27 TFAP2C transcription factor AP-2 gamma
201688_s_at 5.9 <10 4.99 TPD52 tumor protein D52
210715_s_at 7.47 3.28 9.34 SPINT2 serine peptidase inhibitor, Kunitz
219850_s_at 8.32 4.97 14.41 EHF ets homologous factor
208083_s_at 8.86 <10 15.89 ITGB6 integrin, beta 6
207291_at 9.56 <10 14.41 PRRG4 proline rich G-carboxyglutamic acid4
203780_at 9.86 7.23 17.74 EVA1 epithelial V-like antigen 1
204351_at 19.86 4.01 12.57 S100P S100 calcium binding protein P
201839_s_at 32.09 4.59 9.98 TACSTD1 tumor-assoc. ca signal transducer 1
202489_s_at 36.28 3.28 10.64 FXYD3 FXYD domain ion transport reg 3
209772_s_at 49.1 3.69 28.73 CD24 CD24 molecule
Genes with >3-fold differential expression across all three comparisons are shown, together with the extent of differential expression in each data set.
The data are from (1) paclitaxel- versus salinomycin-treated HMLER cells, (2) primary humanmammary epithelial cells grown either in suspension colo-
nies or in adherent conditions (Dontu et al., 2003), and (3) normal and neoplastic human mammary epithelial populations enriched for either CD44+ or
CD24+ cells (Shipitsin et al., 2007). Genes reported in Dontu et al. (2003) as being expressed in only one of the two conditions compared are shown as
having a greater than 10-fold change in expression.656 Cell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc.
may nonetheless be capable of maintaining an already-estab-
lished tumor for an extended period of time. Either of these
possibilities would compromise the therapeutic utility of agents
that exclusively target CSCs. One strategy to address this
concern would be to look for agents that target both the CSCs
and non-CSCs within tumors. Alternatively, it may be preferable
to develop combination therapies that apply agents with specific
toxicity for CSCs together with agents that specifically target
non-CSC populations within tumors.
Due to practical considerations related to compound avail-
ability, the current study was focused largely on the anti-CSC
properties of a single agent, salinomycin. However, our experi-
ments indicate that 30% of the primary screen hits exhibit
EMT-specific toxicity upon retesting. Therefore, it is likely that
expanding the breadth and scope of the current screen to larger
library collections will result in the discovery of additional agents
of therapeutic interest.
EXPERIMENTAL PROCEDURES
Cell Culture
HMLE and HMLER cells expressing either control shRNA (shCntrl) or shRNA
targeting E-cadherin (shEcad) were generated and maintained in a 1:1 mixture
of DMEM + 10% FBS, insulin, hydrocortisone, and MEGM. GFP-expressing
HMLE and HMLE-shEcad cell strains were generated by infection with retro-
virus encoding the pWZL-GFP plasmid. SUM159 cells (Asterand) were
cultured in F12 + 5% FBS, insulin, and hydrocortisone. 4T1 cells (ATCC)
were maintained in RPMI + 10% FBS.
Mammosphere formation assays were performed as described (Dontu et al.,
2003), but with 0.5%methylcellulose (Stem Cell Technologies). One thousand
cells were plated per well in low-adherence 96-well plates and cultured for
7–10 days prior to being counted and photographed.
Antibodies
Antibodies used for immunoblotting were as follows: E-cadherin, N-cadherin
(BD Transduction), Vimentin V9 (NeoMarkers), Actin (Abcam), H-Ras (Santa
Cruz), and Cytokeratin 8 (Troma-1, Developmental Studies Hybridoma Bank,
University of Iowa). Western blotting was performed as previously described
(Onder et al., 2008). Antibodies used for immunohistochemistry were as
follows: pan-cytokeratin (clonesAE1/AE3&PCK26, VentanaMedical Systems),
Vimentin (3B4, Ventana and V9, Vector Labs), caspase-3 (Asp175, Cell
Signaling), and E-cadherin (ECH-6, Ventana and Vector Labs). Immunohisto-
chemistry procedures were performed as previously described (Gupta et al.,
2005).
Fluorescence-Activated Cell Sorting
APC-conjugated anti-CD44 (clone G44-26) antibody, PE-conjugated anti-
CD24 antibody (clone ML5), and propidium iodide (5 mg/ml) were obtained
from BD Biosciences and used for fluorescence-activated cell sorting
(FACS) analysis in accordance with the manufacturer’s protocols.
Characterization of Resistance to Cytotoxic Agents
All compounds were purchased from Sigma and dissolved in DMSO. Cells
(5000/well) were plated in 100 ml per well in 96-well plates. One day (24 hr) after
seeding, compounds were added in five replicates per concentration for each
cell line. Cell viability was measured after 72 hr with the CellTiter96 AQueous
Non-radioactive Assay (Promega).
For cell mixture experiments, unlabeled and GFP-labeled cells were mixed
and seeded into 6-well plates. Wells were compound treated in triplicate for
48 hr prior to FACS.
Chemical Screen and Analysis
Chemical screening was conducted at the Chemical Biology Platform of the
Broad Institute. Cells were seeded in 40 ml of medium containing 1000 cellsper well into white 384-well opaque-bottom plates (Nunc, Rochester, NY)
using an automated plate filler (Bio-Tek mFiller; Winsooki, VT). At 24 hr, 100 nL
of compound solutionswere pin transferred from stock 384-well plates into the
384-well assay plates containing cells, resulting in 10 mM final concentration
for most compounds.
The HMLEshCntrl and HMLEshEcad lines were each screened in two replicates.
Two kinds of negative control wells were employed for normalization: multiple
DMSO-only control wells (>10% of wells/plate) were present on each
compound assay plate screened, and all wells in at least one assay plate for
each cell line were also treated with DMSO alone. CellTiter-Glo Reagent
(Promega) was added 3 days after compound addition (20 ml/well). Lumines-
cence signal was measured with an automated plate reader (Perkin-Elmer
Envision 1).
The raw intensity data for each well were background-corrected by subtrac-
tion of the median intensities across all control wells on the same plate. The
background-corrected data were used to compute a per-well Z score by
subtraction of the per-plate mean and division by twice the per-replicate
standard deviation. Composite Z scores for each compound/cell line combi-
nation were computed by projection of the vector of normalized replicate
Z scores (ZscoreA, ZscoreB) onto the imaginary vector corresponding to
perfect reproducibility.
Internal compound plate numbers for screened plates were 2158–2167,
2099–2105, 2290–2297, 2403–2407, and Biokin1-2. Primary screening data
have been deposited into Chembank (Screen ID: 1108), a publicly accessible
database (http://chembank.broad.harvard.edu/).
Follow-up Validation of Compounds from Primary Screen
All compounds for follow-up were purchased from Sigma and dissolved in
DMSO, with the exception of Nigericin, which was dissolved in 100% ethanol.
Activity of the compounds were quantified by generation of dose-response
curves for HMLE-shCntrl, HMLE-shEcad, and HMLE-Twist under the same
cell density and culture conditions described for the initial screen.
Animal Experiments
NOD/SCID and Balb/c mice were purchased from Jackson Labs. All mouse
procedures were approved by the Animal Care and Use Committees of the
Massachusetts Institute of Technology and Tufts University School of Medi-
cine and performed in accordance with institutional policies.
For xenograft tumor-seeding studies, the indicated numbers of HMLER-
shCntrl, HMLER-shEcad, or drug-treated (DMSO vehicle control; 10 nM pacli-
taxel; 1 mM salinomycin) HMLER cells were suspended in 100 ml Matrigel
diluted 1:2 in DMEM and injected subcutaneously into NOD-SCID mice.
For drug pretreatment experiments, parental HMLER cells were treated for
1 week and allowed to recover in the absence of drug for 2 weeks prior to injec-
tion in vivo. Tumor incidence was monitored for 60 days after injection. For
syngeneic tumor seeding studies, 4T1 cells were pretreated for 4 days with
paclitaxel (10 nM), salinomycin (4 mM), or DMSO in vitro. Cells were injected
in 30 ml 1:1 Matrigel:DMEM solution into the thoracic and inguinal mammary
glands. For tail-vein injection, 1 3 105 4T1 cells were resuspended in 100 ml
saline. Tumor formation was assayed by palpation. Tumor and tissues were
fixed in 10% buffered formalin. Lung tumor burden was quantified using
Spot Software v4.1.3 on captured images to calculate the mean tumor surface
area.
For in vivo compound treatment studies, 13 106 SUM159 cells were resus-
pended in F12 medium and injected into the fourth inguinal mammary glands
of NOD/SCID mice. Compound treatment was initiated 24 hr after injection.
Animals were administered either ethanol (vehicle), salinomycin (5 mg/kg), or
paclitaxel (5 mg/kg) daily by intraperitoneal injection for 5 weeks.
Tumor Cell Isolation and Tumorsphere Assays
SUM159 tumor tissues were minced and digested for 3 hr with agitation at
37C with collagenase and hyaluronidase. Single-cell suspensions were
plated (30,000 cells/well) in 6-well ultra-low attachment plates (Corning) in
F12 + 5% FBS, insulin, and hydrocortisone. Tumorspheres were cultured for
8 days. Tumorspheres collected from nonadherent cultures were quantified
with a Multisizer 3 Coulter Counter (sizing range of 14–336 mm).Cell 138, 645–659, August 21, 2009 ª2009 Elsevier Inc. 657
4T1 lung nodules were isolated at necropsy under a dissection microscope.
Lung nodules were minced and dissociated 4T1 cells plated in DMEM + 10%
FBS for 7 days.
Microarray Data Collection and Gene Expression Analyses
HMLER breast cancer cells were drug-treated for 1 week (10 nM paclitaxel;
1 mM salinomycin) and cultured in the absence of drug for 3 weeks prior to
RNA isolation. Total RNA was isolated with the RNeasy Mini kit (QIAGEN).
Synthesis of cRNA from total RNA and hybridization/scanning of microarrays
were performed with Affymetrix GeneChip products (HGU133A) as described
in the GeneChip manual. Normalization of the raw gene expression data,
quality control checks, and subsequent analyses were done with the open-
source R-project statistical software (R Development Core Team, 2007)
(http://www.r-project.org/) together with Bioconductor packages. Raw data
files (.CEL) were converted into probe set values by RMA normalization.
After RMA normalization, the t statistic was used to generate a ranked list of
genes that are differentially expressed between salinomycin-treated and pacli-
taxel-treated HMLER cells. GSEA was performed with this preranked list as
described previously (Mootha et al., 2003; Subramanian et al., 2005). The
gene sets used for the analysis were compiled from published sources (Dontu
et al., 2003; Liu et al., 2007; Shipitsin et al., 2007) and are provided in Table S1.
ACCESSION NUMBERS
The gene expression microarray data reported in this paper have been depos-
ited in the Gene Expression Omnibus (GEO) repository with accession number
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